This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions.

The presentation slides which follow this notice and the oral presentation of which it forms part (together, the “Materials”) are personal to the recipient and have been prepared and issued by or on behalf of the Company. For the purposes of the remainder of this notice, the term Materials shall include the presentation, the question-and-answer session that follows the presentation, hard or electronic copies of this document and any other materials distributed at, or in connection with, the presentation. The recipient agrees to return all Materials held by it in relation to this presentation upon the Company’s request.

The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this presentation and any errors therein or omissions therefrom.

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company’s nominated adviser, Joh. Berenberg, Gossler & Co. KG (London branch) (“Berenberg”) has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and accordingly it is a communication made only to persons who (a) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and persons who are otherwise permitted by law to receive it and (b) are an “eligible counterparty” within the meaning of Article 24(2), (3) and (4) of Directive 2004/39/EC (“MiFID”) as implemented into national law of the relevant EEA state (together, the “Relevant Persons”). Any investment or investment activity to which this document relates is only available to the Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to Berenberg immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA).

This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company’s financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as “anticipates”, “expects”, “should”, “intends”, “plans”, “believes”, “outlook”, “seeks”, “estimates”, “targets”, “may”, “will”, “continue”, “project” and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of future results or events. The Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Any statements included in or implied by such forward-looking statements. No statement in the Materials is intended to be nor may it be construed as a profit forecast. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company’s ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as speculative factors including the success of the Company’s and its subsidiaries’ (the “Group”) research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group’s products by customers.

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors’ Report section including the “Principal risks and uncertainties” in the most recent Annual Report & Financial Statements of the Company. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.
National Cancer Institute United States: An estimated 40% of men and women will be diagnosed with cancer during their lifetime

Our Mission: Enable personalized cancer care with a simple blood test to guide treatment, improving patient outcomes and reducing healthcare expenditure

Our Solution: The Parsortix system
- first and only FDA cleared product for harvesting CTCs for subsequent analysis
- ANGLE believes it provides the best sample of a patient’s cancer from a liquid biopsy
- enables effective, affordable, repeat testing of intact cells

© ANGLE plc 2022
First Half Highlights

Breakthrough FDA clearance sets platform for growth

Half year

• FDA De Novo Class II medical device clearance in metastatic breast cancer achieved

• Global pharma services business momentum encouraging

• Prostate cancer partnership established with Solaris Health, a major United States urology group

Post period end

• Positive headline results from ovarian cancer verification study

• Presentation of Pap stain assay, offering low cost CTC analysis solution

• Capital raise of £20.1 million

© ANGLE plc 2022
## Financial Results for six months ended 30 June 2022

### Statement of Comprehensive Income

<table>
<thead>
<tr>
<th></th>
<th>Six months ended 30 June 2022</th>
<th>Six months ended 30 June 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>£419</td>
<td>£296</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>(160)</td>
<td>(77)</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>259</td>
<td>219</td>
</tr>
<tr>
<td><strong>Operating costs (net of grant income)</strong></td>
<td>(10,625)</td>
<td>(8,881)</td>
</tr>
<tr>
<td><strong>Tax credit and net finance costs</strong></td>
<td>1,145</td>
<td>979</td>
</tr>
<tr>
<td><strong>Loss for the period</strong></td>
<td>(9,221)</td>
<td>(7,683)</td>
</tr>
</tbody>
</table>

### Statement of Financial Position

<table>
<thead>
<tr>
<th></th>
<th>30 June 2022</th>
<th>31 December 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trade and other receivables and R&amp;D tax credit</strong></td>
<td>7,715</td>
<td>5,779</td>
</tr>
<tr>
<td><strong>Inventories</strong></td>
<td>1,734</td>
<td>1,748</td>
</tr>
<tr>
<td><strong>Cash</strong></td>
<td>20,497</td>
<td>31,839</td>
</tr>
<tr>
<td><strong>Property, plant and equipment and right-of-use assets</strong></td>
<td>8,266</td>
<td>4,376</td>
</tr>
<tr>
<td><strong>Intangible assets</strong></td>
<td>3,590</td>
<td>3,573</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>41,802</td>
<td>47,315</td>
</tr>
</tbody>
</table>

### Comments

- Revenue increased by 42%
- Gross margin at 62%
- Planned expenditure of £10.6 million
- Cash position of £20.5 million
- R&D tax credit due of £4.5 million
- Fundraise of £18.9 million (net) July 2022

© ANGLE plc 2022
# Multi-pronged commercialisation strategy

## Business areas

- **Pharma services** clinical trials business and potential for CDx fully funded business model

- **Medtech partnership** seeking deals with downstream analysis companies to leverage sales channels and fund commercialisation

- **Product business** expanding existing research sales to clinical labs, setting up distributors to broaden sales effort

## Key commercialisation drivers

- **Regulatory clearance** FDA and CE mark in place

- **Clinical studies** run in real world conditions showing value of system, such as ovarian cancer study

- **Clinical laboratories** act as accelerators and demonstrators

- **Product development** to provide end-to-end solutions such as Pap staining

- **Reimbursement codes** with high priority to secure a code for Parsortix separation
FDA clearance recognized as the gold standard

**First ever FDA clearance** for a device to harvest cancer cells from blood for subsequent analysis

- **enabling platform** for end users to develop clinical applications
- ahead of known competition with over six years of clinical development already completed
- initial focus on metastatic breast cancer with plan to extend into other cancer types

---

**INTENDED USE**

The Parsortix® PCI system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K$_2$EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PCI system for use in subsequent downstream assays.

The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
FDA product clearance provides first mover advantage

Post FDA clearance momentum

• **Enhanced** engagement post FDA with discussions initiated with two medtech companies, more than twenty biopharma companies and one Government body

• Outbound engagement increased with **direct marketing**

• Provides a strong indicator of potential future demand for commercial contracts

• Potential to become **the de facto industry standard** for the “best sample”

• Seeking to enable the entire industry

---

**Professor Dr. Naoto T. Ueno**
MD Anderson Cancer Center

“Liquid biopsy to collect circulating live cancer cells is an **essential tool**. We anticipate that the Parsortix FDA clearance may help to develop novel biomarkers, therapeutic approaches and contribute to selecting the best treatment for metastatic breast cancer patients.”

**Professor James M. Reuben**
MD Anderson Cancer Center

“We look forward to the further development of CTC based assays that may bring **enormous benefits to patients with MBC as well as other cancers in the future.”**
Differentiated pharma services offering

• **Customer base established and growing**
  – four customers secured to date, repeat business with two early customers
  – numerous others in discussion
  – anticipated to be the first significant revenue generator for ANGLE

• **Significant revenue and profitability potential**
  – each contract can be over US$1 million
  – margins over 75%
  – each customer can offer numerous repeat contracts
  – only a small number of large-scale pharma customer relationships opens up a very large market

• **Assay development capability**
  – offers pharma bespoke services not possible otherwise
  – targeting the protein of action of the drug
  – cannot be achieved with ctDNA
  – longitudinal monitoring not possible with tissue biopsy

• **CRO out-source growth potential**

---

Howard I. Scher, MD Medical Oncologist
Head of the Biomarker Development Program; D. Wayne Calloway Chair in Urologic Oncology Prostate Cancer

Dr Scher identifies the presence or absence of CTCs as being the best biomarker to assess the effectiveness of a treatment. This enables the early determination of whether a drug is efficacious for a particular patient and might speed up clinical trials and greatly reduce pharma costs

## Pharma services – multi-US$bn growth opportunity in multiple cancers

### Targeted cancer treatment

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Breast cancer</th>
<th>Prostate cancer</th>
<th>Ovarian cancer</th>
<th>NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANGLE supporting data:</td>
<td>26 publications 2 clinical trials</td>
<td>11 publications 2 planned clinical trials</td>
<td>3 publications 2 clinical trials</td>
<td>14 publications</td>
</tr>
<tr>
<td>Active industry sponsored trials:</td>
<td>950 studies in c.247,000 patients</td>
<td>471 studies in c.100,000 patients</td>
<td>398 studies in c.72,000 patients</td>
<td>1,037 studies in c.215,000 patients</td>
</tr>
<tr>
<td>Actionable biomarkers:</td>
<td>BRCA1/2 HER2 ER PR CDK4/6 mTOR</td>
<td>PIK3CA PD-L1 MSI MMR TMB NTRK</td>
<td>BRCA1/2 ATM CHEK2 PALB2 FANCA RAD51D CDK12 MSI MMR</td>
<td>BRCA1/2 MSI MMR TMB NTRK ALK BRAF EGFR KRAS NTRK RET ROSI MET PD-L1 HER2</td>
</tr>
<tr>
<td>TAM:</td>
<td>&gt;$1.0bn</td>
<td>&gt;$410m</td>
<td>&gt;$260m</td>
<td>&gt;$850m</td>
</tr>
</tbody>
</table>

The Mismatch Repair (MMR) system comprises at least ten proteins including MLH1, MSH2, MSH6, and PMS2, which are the most frequent mutated genes in cancer.

© ANGLE plc 2022
Sales and distribution network being established

- **Direct sales team** being expanded in United States and UK
- **Distribution partners** selected for other key territories based on:
  - local knowledge and language
  - exposure to oncology markets
  - compliance with quality systems
  - technical expertise and service capability
Products under development to drive adoption

• Pap staining solution

• Portrait+ IF stained cells for epithelial, EMTing and mesenchymal cell identification

• Portrait+ PD-L1 assessing PD-L1 status key target for immunotherapy

• Portrait+ DNA damage assessing DNA damage on cells with application in drug trials for PARP inhibitors (assay development funded by customer)

• Landscape+ NGS multiple collaborative projects in progress with aim of developing DNA and RNA targeted gene panels for molecular evaluation on CTCs
Pap stain assay potential to accelerate adoption

• Simple, low cost CTC test designed to fit into existing pathology workflows

• **Utilises Pap staining process widely used for cervical smears**

• Test based on expertise of qualified cyto-technologist fast tracks potential use in clinical laboratories

• Presented at the 100th American Society for Clinical Pathology meeting and nominated as a finalist for a prestigious ‘Blue Ribbon’ Laboratory Management award

• Simple method to assess presence of cancer cells
Real world clinical validity study

Ovarian cancer – positive headline results

“The next generation ANGLE pelvic mass triage test has the ability to out-perform current clinical practice in accurately discriminating malignant from benign pelvic masses prior to biopsy or surgery. The improved accuracy of the test results in a high level of sensitivity as well as a substantial reduction in false positives.”

Dr Richard Moore
Director of the Gynecologic Oncology Division, University of Rochester Medical Center Wilmot Cancer Institute

• Excellent results in ovarian cancer with ROC-AUC 95.4% based on molecular analysis of Parsortix harvest
• Sensitivity 90%, Specificity 93% maintaining best in class performance
• 50% or greater reduction in false positives and false negatives
• Strong clinical validation in this difficult to diagnose setting
  – demonstrating ability to undertake complex molecular analysis of the Parsortix harvest
  – confirming its suitability for use in both hospital laboratories and central laboratories requiring sample shipping
• Finalising detailed plans for commercialisation of Parsortix Landscape+ molecular assays
Real world clinical validity study
Prostate cancer in collaboration with Solaris Health

Agreement signed with MidLantic Urology
• MidLantic Urology, affiliate of Solaris Health Partners
• >500 providers across 179 locations in 9 States with 729,000 patients p.a.
• Solaris Health to provide first route to market

Study design
• 100 patients scheduled to undergo prostate tissue biopsy
• Study will be conducted at 3 study sites in Pennsylvania over 9-month period
• Test to predict presence of clinically significant prostate cancer
• Headline results anticipated late 2023

“Preliminary data suggests that we may be able to create an assay for the detection of clinically significant prostate cancer that has high specificity and sensitivity. Moreover, the assay can be customized to operate in a wide spectrum of prostate cancer disease states, including pre-prostate biopsy, after a negative biopsy, active surveillance, after local failure, and in early and late metastatic disease states.”

Dr Jose Moreno, Principal Investigator, MidLantic Urology

© ANGLE plc 2022
Focus on near-term strategic and commercial imperatives

Immediate Priorities

- **Launch of FDA cleared and CE Marked system** in United States and RoW
  - secure leading clinical laboratories as reference customers
- **Expand pharma services business**
  - additional customers and repeat business
- **Corporate deals** medtech, pharma, clinical labs (numerous discussions ongoing)
- **Secure accreditation** for Onc-ADaPT laboratories

Plan to drive future growth

- **Distributor network**
- **Roll out of products**
  - low cost Pap stain CTC solution
  - Portrait⁺ / Portrait⁺ PD-L1 / Portrait⁺ DNA damage
  - Landscape⁺ NGS targeted panels
- **Clinical studies**
  - excellent ovarian cancer results
  - prostate cancer with Solaris
  - third party Lianidou PD-L1 immunotherapy study, Aceto “cluster buster” drug trial
- **Secure reimbursement code** for Parsortix
ANGLE positioned for commercial growth

• FDA clearance a major breakthrough bringing global recognition

• First mover advantage in a very large market with high barriers to entry

• ANGLE now in position to capitalise with multiple corporate partnerships with leading medtech and pharma companies in discussion

• First large-scale pharma services contract secured and repeat business won

• Multiple potential catalysts over next 12 - 18 months
Questions and answers